Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
281results about "Living procariotic cell medical ingredients" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
ActiveUS20110280840A1Increased use of antibioticIncreasing adult height and muscle massBiocideMetabolism disorderIntestinal microorganismsBone formation
The present invention relates to characterizing changes in mammalian gastrointestinal microbiota associated with antibiotic treatment and various disease conditions (such as obesity, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, glucose intolerance, diabetes, non-alcoholic fatty liver, abnormal lipid metabolism, short stature, osteoporosis, and other disorders of bone formation and mineralization, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of probiotics, prebiotics, or narrow spectrum antibiotics / anti-bacterial agents that are capable of restoring healthy mammalian bacterial gastrointestinal microbiota.
Owner:NEW YORK UNIV
Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
ActiveUS20120172319A1Improve immune system systemImprove system enteric nervous systemOrganic active ingredientsBiocideDiseaseMorbidity aspects
Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.
Owner:ABBOTT LAB INC
Genetically programmable pathogen sense and destroy
InactiveUS20120027786A1Easy to deployWide range of applicationsAntibacterial agentsBiocideSomatosensory systemPathogen
Owner:MASSACHUSETTS INST OF TECH
Composition Comprising Anaerobically Cultivated Human Intestinal Microbiota
The invention relates to an anaerobic micro-ecological system, a composition comprising anaerobically cultivated human intestinal microbiota for the treatment or prophylaxis of diseases, and wherein the microbiota in the composition have not been exposed to antibiotics used after 1995. The present invention further relates to the use of the composition for the prevention and treatment of disease and a method for preparing the composition.
Owner:ACHIM BIOTHERAPEUTICS
Novel strain of bacillus amyloliquefaciens and its use
InactiveUS20100143316A1Inhibits pathogenic growthPromote biodegradationAntibacterial agentsBiocideBiotechnologyAmylase
An isolated Bacillus amyloliquefaciens Ba-BPD1 having an Accession No. of DSM 21836 is provided. This novel strain has unique 16S ribosomal RNA sequenced as SEQ ID NO:1 and produces amylase, protease, cellulase and lipase, fibrinolytic enzyme to show their biodegradation capacities. Further, B. amyloliquefaciens Ba-BPD1 produces the antibiotic substances, such as iturin, fengycin and surfactin, and has antimicrobial capacity for inhibiting the fungal or bacterial growth. In conclusion, the novel strain of Bacillus amyloliquefaciens Ba-BPD1 and its products can be applied in agriculture, wastewater treatment, food industry and chemical industry.
Owner:AGRI CHEM & TOXIC SUBSTANCES RES INST COUNCIL AGRI EXECUTIVE YUAN
Methods of treating pigs with bacillus strains
Disclosed are methods of administering at least two Bacillus strains to a pig, such as female breeding stock, nursery pigs, or other pigs. The Bacillus strains inhibit Clostridium in litters borne to the pig. The Bacillus strains also are useful when administered to herds lacking symptoms of Clostridium infection. Administration of the Bacillus strains improves performance of female breeding stock and in piglets borne by the female breeding stock.
Owner:DUPONT NUTRITION BIOSCIENCES APS
Thraustochytrids, Fatty Acid Compositions, and Methods of Making and Uses Thereof
Owner:DSM IP ASSETS BV
Compositions of microbiota and methods related thereto
Methods and compositions are generally provided for treating metabolic disorders, e.g., obesity. One aspect discloses methods and compositions for obtaining a biological sample from the subject, evaluating the sample for the presence or absence of a genetic indicator, wherein the genetic indicator is selected from a single nucleotide polymorphism and a level of gene expression, and performing a first metabolic procedure if the genetic indicator is present, or performing an alternative second metabolic procedure if the genetic indicator is absent. One aspect discloses methods and compositions for obtaining a sample including deoxyribonucleic acids (DNA) from the subject, evaluating the DNA for an absence or presence of one or more genetic indicators and performing a first metabolic procedure or an alternative second metabolic procedure based on the absence or presence of the genetic indicator(s). Other aspects are also disclosed.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Compositions comprising bacterial strains
ActiveUS20170143774A1Great tasteMoreAntibacterial agentsSenses disorderAutoimmune conditionAutoimmune disease
Owner:ARMISTICE CAPITAL MASTER FUND LTD +1
Cyclic di-amp induction of type i interferon
InactiveUS20120164107A1Increase secretionDecrease c-di-AMP phosphodiesterase activityBiocideBacteriaCyclaseProtein composition
Methods of modulating type-I interferon production in a cell are provided. Aspects of the methods include modulating cytosolic cyclic di-adenosine monophosphate (c-di-AMP) activity in the cell in a manner sufficient to modulate type-I interferon production in the cell. Additional aspects of the invention include c-di-AMP activity modulatory compositions, e.g., c-di-AMP, mutant Listeria bacteria, cyclase and / or phosphodiesterase nucleic acid or protein compositions, etc. The subject methods and compositions find use in a variety of applications, including therapeutic applications.
Owner:RGT UNIV OF CALIFORNIA
Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
InactiveCN104160014APromote proliferationPromote accumulationBacteriaAntipyreticBacteroidesRegulatory T cell
Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
Owner:THE UNIV OF TOKYO +1
Methods of treating pigs with Bacillus strains
Disclosed are methods of administering at least two Bacillus strains to a pig, such as female breeding stock, nursery pigs, or other pigs. The Bacillus strains inhibit Clostridium in litters borne to the pig. The Bacillus strains also are useful when administered to herds lacking symptoms of Clostridium infection. Administration of the Bacillus strains improves performance of female breeding stock and in piglets borne by the female breeding stock.
Owner:DUPONT NUTRITION BIOSCIENCES APS
Bacillus based delivery system and methods of use
ActiveUS20100233124A1Stimulate immune responseSlow onsetBiocideSsRNA viruses positive-senseSurface displaySpore
Herein a Bacillus exosporium antigen delivery (BEAD) system that provides a means to introduce recombinant proteins or small molecules into the exosporium of members of the B. cereus family of bacteria, i.e. B. anthracis, B. cereus, and B. thuringiensis, is disclosed. The system results in the surface display of recombinant proteins or small molecules such that they can stimulate an immune response. In addition, methods of making and using the system are described.
Owner:UNIVERSITY OF MISSOURI
Lactobacillus plantarum having anti-diabetic function and application thereof
InactiveCN105567586APromote growthImprove acid resistanceBacteriaMetabolism disorderLactobacillusSide effect
Lactobacillus plantarum having an anti-diabetic function and application thereof are disclosed, the strain is Lactobacillus plantarum NCU116, and the accession number is CGMCC 11885. The strain has a function to alleviate symptoms of diabetes, and the composition is in a form of food or a pharmaceutical composition. The present invention also discloses a method for screening and identification of the lactic acid bacteria strain as well as a method to achieve the anti-diabetic effect by regulating blood sugar, blood lipids and hormone levels and regulating metabolic pathways in the body. The daily-intake lactic acid bacteria or a composition thereof is used to replace a medicine to achieve the anti-diabetic effect; and the healthy daily-intake lactic acid bacteria or the composition thereof is free of toxic and side effects to human body is used as a new choice to alleviate the symptoms of diabetes.
Owner:NANCHANG UNIV
Probiotic Stabilization
InactiveUS20110070334A1Improve biostabilityPeptide/protein ingredientsLactobacillusProbioticChemistry
Owner:MEAD JOHNSON NUTRITION
Compositions of microbiota and methods related thereto
Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Novel strain of bacillus amyloliquefaciens and its use
InactiveUS20150147303A1Inhibits pathogenic growthPromote biodegradationBiocideFruit and vegetables preservationBacteroidesBacilli
An isolated Bacillus amyloliquefaciens Ba-BPD1 having an Accession No. of DSM 21836 is provided. This novel strain has unique 16S ribosomal RNA sequenced as SEQ ID NO:1 and produces amylase, protease, cellulase and lipase, fibrinolytic enzyme to show their biodegradation capacities. Further, B. amyloliquefaciens Ba-BPD1 produces the antibiotic substances, such as iturin, fengycin and surfactin, and has antimicrobial capacity for inhibiting the fungal or bacterial growth. In conclusion, the novel strain of Bacillus amyloliquefaciens Ba-BPD1 and its products can be applied in agriculture, wastewater treatment, food industry and chemical industry.
Owner:HSIEH FENG CHIA
Strain of Lactobacillus plantarum and uses thereof
A novel strain of Lactobacillus plantarum, referred to as LB931, has now been isolated. The strain has been deposited at Deutsche Sammlung von Mikroorganismen, Braunschweig, DE. It has been assigned accession number DSM11918. Accordingly LB931 can be used for treating and / or preventing urogenital infections. LB931 can advantageously be included in pharmaceutical compositions and in products for personal care, such as feminine hygiene products, diapers and sanitary napkins.
Owner:SCA HYGIENE PROD AB
Compositions comprising bacterial strains
Provided are compositions comprising a bacterial strain of the genus Blautia, for use in a method of increasing the microbiota diversity and / or inducing stability of the microbiota of a subject.
Owner:4D PHARMA +1
Use of live bacteria for growth promotion in animals
The present invention relates to the use of F4+ non-pathogenic Escherichia coli strains to promote growth in an animal. The present invention also relates to the use of such strains to homogenize growth among a herd of animals. More specifically, the animal(s) of interest in the present invention are those wherein growth promotion or growth homogenization are desired goals, such as animals reared for meat production. The present invention further relates to a method for promoting growth of an animal as well as a method for homogenizing growth among a herd of animals.
Owner:ELANCO CANADA LTD
Plasmid maintenance
ActiveUS7611883B2Inhibit transcriptionAvoid actionBacteriaLiving procariotic cell medical ingredientsCell growthIn vivo
The invention relates to a system for stable maintenance of a plasmid, to host cells for use in this system and to methods of using the system to obtain a plasmid useful in medical applications. In particular, the invention provides transformed host cell containing: i) a chromosomal gene which inhibits cell growth; and ii) a plasmid encoding an antisense sequence, wherein the antisense sequence encoded by the plasmid inhibits the action of the chromosomal gene, thereby permitting cell growth and a method for stable maintenance of a plasmid in a host cell in vivo.
Owner:BOEHRINGER INGELHEIM RCV GMBH & CO KG
Lactobacillus rhamnosus capable of relieving chronic alcohol liver injury and application thereof
Owner:JIANGNAN UNIV
Compositions comprising bacterial strains
Owner:4D PHARMA +1
Compositions comprising bacterial strains
Owner:ARMISTICE CAPITAL MASTER FUND LTD +1
Compositions and methods of enhancing immune responses
ActiveUS8604178B2Enhance immune responseReduce morbiditySsRNA viruses negative-senseBacteriaSalmonella enteritidisBacilli
Provided herein are Salmonella enteritidis 13A strains and compositions comprising these strains. Also provided are methods of enhancing an immune response against Influenza A and methods of reducing morbidity associated with an Influenza A infection. Methods of enhancing an immune response to a vaccine vector by expressing a polypeptide of CD 154 capable of binding CD40 are also disclosed. Methods of developing a bacterial vaccine vector are disclosed. Methods of generating scarless site-specific mutations in a bacterium are also disclosed.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ARKANSAS +1
Compositions comprising bacterial strains
Owner:ARMISTICE CAPITAL MASTER FUND LTD +1
Compositions comprising bacterial strains
Owner:CJ BIOSCIENCE INC +1
Novel bacteria isolated from fresh honey or the honey producing tract of honey bees
ActiveUS20100086528A1Effective strikeUnique health promoting propertiesAntibacterial agentsBiocideBacteroidesBifidobacterium
The invention relates to new isolated Lactobacillus and Bifidobacterium strains which have been isolated from fresh honey having a water content above 18% by weight or from the honey producing tract of at least one bee. The bacterial strains have unique properties rendering them useful in many products such as in food and beverage products, feed products and medica products.
Owner:OLOFSSON +1
Method and system for treating cancer cachexia
ActiveUS9730967B2Foster the retention of muscle mass in the individualRestore healthPeptide/protein ingredientsHydrolasesMuscle tissueCancer cell
Various embodiments of the present invention are directed to the field of Oncology, and in particular embodiments directed to a method of ameliorating, treating, or preventing a malignancy in a human subject wherein the steps of the method assist or boost the immune system in eradicating cancerous cells. In certain embodiments, administration of beneficial bacteria to an individual's microbiome that have been modified so as to produce effective amounts of desired compositions, compounds, agents, e.g. tomatidine, p53 protein, statins, etc., is employed to address cancerous conditions. In several embodiments, the administration of such beneficial bacteria and microbes to an individual's microbiome invokes either an active (or a passive) immune response to destroy, weaken or render less invasive certain cancerous cells, and preferably maintains muscle tissue to combat cancer cachexia.
Owner:KOVARIK JOSEPH E +1
Method and System for Treating Cancer Cachexia
ActiveUS20170173085A1Good lookingFoster the retention of muscle mass in the individualHydrolasesPeptide/protein ingredientsMuscle tissueCancer cell
Various embodiments of the present invention are directed to the field of Oncology, and in particular embodiments directed to a method of ameliorating, treating, or preventing a malignancy in a human subject wherein the steps of the method assist or boost the immune system in eradicating cancerous cells. In certain embodiments, administration of beneficial bacteria to an individual's microbiome that have been modified so as to produce effective amounts of desired compositions, compounds, agents, e.g. tomatidine, p53 protein, statins, etc., is employed to address cancerous conditions. In several embodiments, the administration of such beneficial bacteria and microbes to an individual's microbiome invokes either an active (or a passive) immune response to destroy, weaken or render less invasive certain cancerous cells, and preferably maintains muscle tissue to combat cancer cachexia.
Owner:KOVARIK JOSEPH E +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com